Clusterin levels can be used to predict Alzheimer's onset
( high clusterin had high levels of plaques in the brain )
Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it.
DONATE NOW
Your Alzheimer's donation will help billions live without it.
DONATE NOW
Scientists have suggested that levels of the protein called clusterin rise 'many years' before symptoms of Alzheimer's disease first appear.
An early test for the condition could allow those patients could have early treatment and make improvements to their lifestyle to minimise the impact of the disease.
The study, conducted by the Institute of Psychiatry at King's College London, also found that very high levels of the protein may be linked with more rapid and severe memory loss.
Patient groups said the prospect of a blood test for Alzheimer's disease was the 'holy grail' for researchers in this area and the latest findings bring this a step closer.
Alzheimer's disease is the most common form of dementia in Britain and affects almost 500,000 people. This is expected to double by 2050 as the population ages.
The ethics of any blood test to identify those in the very early stages of Alzheimer's disease would need to be examined carefully as there is no cure for the condition.
The researchers compared blood samples taken from 300 people with either Alzheimer's disease, mild impairment or normal brain function.
The found that clusterin levels were linked with Alzheimer's symptoms and higher levels indicated more rapid and severe memory loss and brain shrinkage as shown on brain scans.
Experiments with mice showed that the protein is produced in increasing amounts with age and is also linked to the development of plaques in the brain which interfere with cell communications systems. The clusterin surrounded the plaques.
It is not known if the plaques are the cause of Alzheimer's disease or a sign of it but this research has shown that the body produces greater quantities of clusterin along with the plaques and it may be an attempt to protect the brain from the build up of the plaques.
Therefore high levels of clusterin, which can be detected in a blood sample, could be used as an early warning sign that the body is already fighting Alzheimer's disease.
Read more: medilexicon.comThe study, conducted by the Institute of Psychiatry at King's College London, also found that very high levels of the protein may be linked with more rapid and severe memory loss.
Patient groups said the prospect of a blood test for Alzheimer's disease was the 'holy grail' for researchers in this area and the latest findings bring this a step closer.
Alzheimer's disease is the most common form of dementia in Britain and affects almost 500,000 people. This is expected to double by 2050 as the population ages.
The ethics of any blood test to identify those in the very early stages of Alzheimer's disease would need to be examined carefully as there is no cure for the condition.
The researchers compared blood samples taken from 300 people with either Alzheimer's disease, mild impairment or normal brain function.
The found that clusterin levels were linked with Alzheimer's symptoms and higher levels indicated more rapid and severe memory loss and brain shrinkage as shown on brain scans.
Experiments with mice showed that the protein is produced in increasing amounts with age and is also linked to the development of plaques in the brain which interfere with cell communications systems. The clusterin surrounded the plaques.
It is not known if the plaques are the cause of Alzheimer's disease or a sign of it but this research has shown that the body produces greater quantities of clusterin along with the plaques and it may be an attempt to protect the brain from the build up of the plaques.
Therefore high levels of clusterin, which can be detected in a blood sample, could be used as an early warning sign that the body is already fighting Alzheimer's disease.
Creatine at low doses promotes resistance to fatigue
Creatine, an amino acid-like compound, was first identified in 1832 for its presence in muscle. It has been the subject of about 70 randomized, controlled trials over the last 12 years or so, with the majority investigating creatine’s performance-enhancing benefits. Read more: nutraingredients.com
No comments:
Post a Comment